EligibleTrials

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Recruiting · NCT07577843 · Interventional (participants receive a specific treatment) · Lead sponsor: Janssen Research & Development, LLC

View the official record on ClinicalTrials.gov →
Crohn's disease

Interventions studied

GuselkumabJNJ-78934804

What this trial is about

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed across 15 US states.

Showing 60 of 142 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.